Skip to content
    Reviews

    Umbrella Review Finds Low-Quality Evidence for Procalcitonin in Medullary Thyroid Carcinoma

    Petranović Ovčariček et alJournal of Clinical Medicine

    Umbrella Review Finds Low-Quality Evidence for Procalcitonin in Medullary Thyroid Carcinoma
    An umbrella review evaluated the quality and literature overlap among systematic reviews investigating procalcitonin as an alternative or complementary biomarker to calcitonin in medullary thyroid carcinoma (MTC). Across database searches of PubMed/MEDLINE and the Cochrane Library conducted to 30 June 2026, the authors included seven evidence syntheses published between 2015 and 2024, of which four addressed procalcitonin directly and two included quantitative meta-analyses.
    Across combined diagnostic and monitoring cohorts, a bivariate meta-analysis encompassing 11 studies and 5,817 patients reported a pooled sensitivity of 0.90 (95% CI 0.71–0.97) and a pooled specificity of 1.00 (95% CI 0.85–1.00). In postoperative surveillance cohorts, pooled estimates from five studies and 296 patients yielded both sensitivity and specificity of 96%.
    However, critical methodological limitations and substantial redundancy were identified across the literature. Five syntheses providing primary reference details relied on only 21 distinct primary reports, generating a corrected covered area (CCA) of 38.1%, with every pairwise comparison exceeding the 15% threshold indicating very high study overlap. Methodological evaluation using AMSTAR-2 rated confidence as low for one review and critically low for the remaining six reviews. Furthermore, discordant data extraction occurred across reviews; in one primary study, differing assay platforms and applied thresholds yielded markedly divergent reported specificities of 84% versus 5% for identical underlying data.
    The authors concluded that while procalcitonin represents a promising adjunct to calcitonin with better analytical behaviour, routine combined testing is not yet supported. The apparent consistency among existing evidence syntheses reflects shared reliance on a limited primary evidence base rather than independent replication, and the lack of an agreed, method-specific diagnostic threshold remains the primary obstacle to clinical adoption.

    Key Takeaways

    • Across diagnostic and monitoring populations, a bivariate meta-analysis of 11 studies comprising 5,817 patients yielded a procalcitonin sensitivity of 0.90 (95% CI 0.71–0.97) and specificity of 1.00 (95% CI 0.85–1.00), while postoperative surveillance across five studies and 296 patients yielded pooled sensitivity and specificity of 96%.
    • AMSTAR-2 methodological quality appraisal found confidence was low for one systematic review and critically low for six, accompanied by very high primary study overlap (corrected covered area of 38.1%) and discordant data extraction that produced specificities varying between 84% and 5% for the same primary dataset depending on assay platform and threshold.
    • Routine combined measurement of procalcitonin alongside calcitonin is not yet supported in clinical practice due to reliance on a narrow shared primary literature and the absence of an agreed, method-specific threshold.
    Read the original sourceJournal of Clinical Medicine